The FIRST and ONLY immunotherapy approved in the first-line maintenance setting for patients with locally advanced or metastatic urothelial carcinoma
BAVENCIO® (avelumab) is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.